Health

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 24/10/2026, 23:06:25 UTC.

Briefings

Novartis' remibrutinib treatment significantly reduced relapse rates in multiple sclerosis trials compared to a standard treatment, achieving a 35.2% reduction in the first study and 31.2% in the second. While this efficacy is lower than Roche's fenebrutinib, the new drug offers a cleaner safety profile, potentially allowing it to compete in the market. The findings were presented at an MS conference in Toronto on October 23, 2026.

Key points

• Novartis' remibrutinib reduced the annualized relapse rate by 35.2% in the first Phase 3 study compared to a standard treatment.
• The same drug reduced the relapse rate by 31.2% in the second Phase 3 study, translating to approximately one relapse every 13 years.

Context

This finding comes from two Phase 3 studies in the relapsing form of MS, where remibrutinib outperformed the standard treatment in relapse reduction. The data was presented by Heinz Wiendl at an MS conference in Toronto on October 23, 2026.

Limitations

The evidence is limited to two Phase 3 studies in the relapsing form of MS. The specific safety profile advantages are inferred from the text rather than confirmed by direct safety data. The study results are from a preprint and may be subject to further review or publication.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 24/10/2026, 23:10:02 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeibb6c4eoeyk7uptrdffe4pg3lo2x4hq3zja4q5jeu7lz34epozhhy